EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Hyaluronic Acid Profhilo® Alleviates Skin Inflammation and Spinal Neuroimmune Alterations in a Mouse Model of Atopic Dermatitis

Gabriel Siquier-Dameto iD, Javier Gimeno-Beltrán, Gilberto Bellia iD, Andrea Giori iD, Pere Boadas-Vaello iD, Enrique Verdú iD

Medicina · 2026

DOI: 10.3390/medicina62020405 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Medicina, 2026. Verfasst von Gabriel Siquier-Dameto und 5 weiteren Autor:innen. Beteiligte Einrichtung: Research Group of Clinical Anatomy, Embryology and Neuroscience (NEOMA), Department of Medical Sciences, University of Girona, 17003 Girona, Spain. Hauptthemen laut MEDLINE: Hyaluronic Acid, Dermatitis, Atopic. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 163 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: IBSA Farmaceutici Italia (S.r.l), Via della Filanda 30, 26900 Lodi, Italy, IBSA Farmaceutici Italia.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Objectives: Hyaluronic acid (HA) is extensively used in dermo-aesthetic medicine for its hydrating and tissue-repairing properties. Beyond cosmetic use, HA has shown therapeutic effects in inflammatory skin diseases such as seborrheic, radiation-induced, and atopic dermatitis (AD). However, HA-based aesthetic formulations such as Profhilo®, a hybrid complex of high- and low-molecular weight HA, have not been tested in immunologically driven models of AD. This study aimed to investigate the therapeutic effects of intradermal Profhilo® injections in a recently developed ovalbumin (OVA)-induced murine model of AD. Specific objectives included assessing changes in skin inflammation, pain sensitivity, and spinal cord pathology. Materials and Methods: Twenty-eight adult female ICR-CD1 mice were sensitized and exposed to OVA via intraperitoneal, subcutaneous, and topical routes over 49 days to induce AD-like lesions. Control animals received saline. On day 50, mice were subdivided into four groups receiving intradermal injections of Profhilo® or saline. Skin inflammation was evaluated using the SCORAD index on days 49 and 57, and nociceptive responses were measured using the plantar thermal hyperalgesia test. On day 57, dorsal skin and thoracic spinal cord samples were collected for histological and immunohistochemical analysis, including assessments of epidermal and dermal thickness, mast cell density, collagen content, CGRP immunoreactivity, and microglial activation.

Results

OVA-treated mice developed significant skin inflammation (p < 0.0001) and thermal hyperalgesia. Intradermal HA injection significantly reduced SCORAD scores (p < 0.01) and mast cell density (p < 0.05) while increasing dermal thickness (p < 0.05). In the spinal cord, HA treatment reduced CGRP immunoreactivity and microglial activation (p < 0.01 and p < 0.05, respectively), especially in OVA-treated animals.

Conclusions

Intradermal Profhilo® alleviated both cutaneous inflammation and neurogenic pain in an OVA-induced AD model. These findings suggest that HA not only improves local skin pathology but also modulates central neuroimmune responses, supporting its therapeutic potential for inflammatory skin conditions involving peripheral and central sensitization.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hyaluronic AcidDermatitis, AtopicAnimalsMiceFemaleDisease Models, AnimalMice, Inbred ICRSkinInflammationSpinal CordOvalbuminInjections, Intradermal

Stichwörter der Autor:innen

atopic dermatitis modelcalcitonin gene-related peptide (CGRP)hyaluronic acidintradermal injectionneuroimmune modulation

Substanzen

Hyaluronic AcidOvalbumin

Autor:innen und Institutionen

  • Research Group of Clinical Anatomy, Embryology and Neuroscience (NEOMA), Department of Medical Sciences, University of Girona, 17003 Girona, Spain.
  • Dameto Clinics International, 07460 Pollensa, Spain.
  • Pathology Department, Hospital del Mar, 08003 Barcelona, Spain.
  • IBSA Farmaceutici Italia, 26900 Lodi, Italy.

ORCID-Profile: Gabriel Siquier-Dameto, Gilberto Bellia, Andrea Giori, Pere Boadas-Vaello, Enrique Verdú

Förderung

  • IBSA Farmaceutici Italia (S.r.l), Via della Filanda 30, 26900 Lodi, Italy
  • IBSA Farmaceutici Italia

Zitieren

APA

Siquier-Dameto, G., Gimeno-Beltrán, J., Bellia, G., Giori, A., Boadas-Vaello, P., & Verdú, E. (2026). Hyaluronic Acid Profhilo® Alleviates Skin Inflammation and Spinal Neuroimmune Alterations in a Mouse Model of Atopic Dermatitis. Medicina. https://doi.org/10.3390/medicina62020405

Vancouver

Siquier-Dameto G, Gimeno-Beltrán J, Bellia G, Giori A, Boadas-Vaello P, Verdú E. Hyaluronic Acid Profhilo® Alleviates Skin Inflammation and Spinal Neuroimmune Alterations in a Mouse Model of Atopic Dermatitis. Medicina. 2026. doi:10.3390/medicina62020405

BibTeX
@article{SiquierDameto2026,
  author = {Siquier-Dameto, Gabriel and Gimeno-Beltrán, Javier and Bellia, Gilberto and Giori, Andrea and Boadas-Vaello, Pere and Verdú, Enrique},
  title = {Hyaluronic Acid Profhilo® Alleviates Skin Inflammation and Spinal Neuroimmune Alterations in a Mouse Model of Atopic Dermatitis},
  journal = {Medicina},
  year = {2026},
  doi = {10.3390/medicina62020405}
}
Kostenlos starten →